Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 131

1.

Diagnostic implications of intrapatient genetic tumor heterogeneity.

Berbegall AP, Navarro S, Noguera R.

Mol Cell Oncol. 2015 Sep 11;3(2):e1079671. doi: 10.1080/23723556.2015.1079671. eCollection 2016 Mar.

PMID:
27308602
2.

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, Øra I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D.

Cancer Lett. 2016 Jun 1;375(2):384-9. doi: 10.1016/j.canlet.2016.02.046. Epub 2016 Mar 18.

3.

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF.

Oncogene. 2016 Mar 21. doi: 10.1038/onc.2016.50. [Epub ahead of print]

PMID:
26996667
4.

Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood.

Berbegall AP, López-Almaraz R, Navarro S, Noguera R.

Expert Rev Neurother. 2016 May;16(5):465-7. doi: 10.1586/14737175.2016.1163221. Epub 2016 Apr 6. No abstract available.

PMID:
26949993
5.

Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.

Tadeo I, Bueno G, Berbegall AP, Fernández-Carrobles MM, Castel V, García-Rojo M, Navarro S, Noguera R.

Oncotarget. 2016 Feb 24. doi: 10.18632/oncotarget.7661. [Epub ahead of print]

6.

The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM.

Int J Cancer. 2016 Jul 1;139(1):153-63. doi: 10.1002/ijc.30050. Epub 2016 Mar 22.

PMID:
26910568
7.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

8.

One-Year Outcome Comparison of Laparoscopic, Robotic, and Robotic Intrafascial Simple Prostatectomy for Benign Prostatic Hyperplasia.

Martín Garzón OD, Azhar RA, Brunacci L, Ramirez-Troche NE, Navarro LM, Hernández LC, Bragayrac LN, Noguera RJ.

J Endourol. 2016 Mar;30(3):312-8. doi: 10.1089/end.2015.0218. Epub 2015 Nov 12.

PMID:
26463701
9.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.

PMID:
26119945
10.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

11.

Critical evaluation of three hemodynamic models for the numerical simulation of intra-stent flows.

Chabi F, Champmartin S, Sarraf C, Noguera R.

J Biomech. 2015 Jul 16;48(10):1769-76. doi: 10.1016/j.jbiomech.2015.05.011. Epub 2015 May 19.

PMID:
26044195
12.

Two independent epigenetic biomarkers predict survival in neuroblastoma.

Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, Hernández M, Segura V, Cañete A, Conesa A, Font de Mora J, Castel V.

Clin Epigenetics. 2015 Feb 27;7(1):16. doi: 10.1186/s13148-015-0054-8. eCollection 2015.

13.

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H.

Int J Cancer. 2015 Aug 15;137(4):868-77. doi: 10.1002/ijc.29461. Epub 2015 Feb 20.

PMID:
25652004
14.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

15.

Anal tuberculosis complicating anti-TNFα therapy.

Luquín N, Masiá M, Noguera R, Gutiérrez F.

BMJ Case Rep. 2014 Nov 24;2014. pii: bcr2014206976. doi: 10.1136/bcr-2014-206976.

PMID:
25422341
16.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

17.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
18.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

19.

Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D.

Int J Cancer. 2015 Mar 1;136(5):E252-61. doi: 10.1002/ijc.29217. Epub 2014 Oct 7.

20.

Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.

Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R.

Neoplasia. 2014 Jun;16(6):471-80. doi: 10.1016/j.neo.2014.05.012.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk